Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $46.4 million.

  • Tango Therapeutics' Non-Current Assets fell 1016.09% to $46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.7 million, marking a year-over-year decrease of 986.05%. This contributed to the annual value of $50.1 million for FY2024, which is 1049.46% down from last year.
  • Latest data reveals that Tango Therapeutics reported Non-Current Assets of $46.4 million as of Q3 2025, which was down 1016.09% from $47.8 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Non-Current Assets registered a high of $166.8 million during Q2 2021, and its lowest value of $7.8 million during Q4 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $53.0 million (2024), whereas its average is $57.2 million.
  • Examining YoY changes over the last 5 years, Tango Therapeutics' Non-Current Assets showed a top increase of 68288.35% in 2022 and a maximum decrease of 9348.3% in 2022.
  • Quarter analysis of 5 years shows Tango Therapeutics' Non-Current Assets stood at $7.8 million in 2021, then surged by 682.88% to $61.2 million in 2022, then decreased by 8.45% to $56.0 million in 2023, then fell by 10.49% to $50.1 million in 2024, then decreased by 7.56% to $46.4 million in 2025.
  • Its last three reported values are $46.4 million in Q3 2025, $47.8 million for Q2 2025, and $49.4 million during Q1 2025.